Development asset linked to Viatris Pharmaceuticals Co in public FDA and regional records.
pharma · Moderate to severe systemic lupus erythematosus · Lupus Erythematosus, Systemic
Viatris Pharmaceuticals Co
Viatris Pharmaceuticals Co.,
Viatris Pharmaceuticals Co drug portfolio — 23 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
FR HQ
4 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- FR
- Employees
- 4
- Programs
- 8
- Drugs
- 23
- Patents
- 0
Viatris Pharmaceuticals Co pipeline
Portfolio lens on 23 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Viatris Pharmaceuticals Co drug portfolio — 23 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
celecoxib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Prostaglandin G/H synthase 2.
- Target
- Prostaglandin G/H synthase 2
- Mechanism
- Cyclooxygenase-2 inhibitor
-
Development asset linked to Viatris Pharmaceuticals Co in public FDA and regional records. Molecular target: Sphingosine 1-phosphate receptor 1.
- Target
- Sphingosine 1-phosphate receptor 1
- Mechanism
- Sphingosine 1-phosphate receptor Edg-1 modulator
-
Development asset linked to Viatris Pharmaceuticals Co in public FDA and regional records. Molecular target: Bile acids.
- Target
- Bile acids
- Mechanism
- Bile acids sequestering agent
-
Development asset linked to Viatris Pharmaceuticals Co in public FDA and regional records. Mechanism: Serotonin 1b (5-HT1b) receptor agonist.
- Mechanism
- Serotonin 1b (5-HT1b) receptor agonist
-
Development asset linked to Viatris Pharmaceuticals Co in public FDA and regional records. Mechanism: Type-1 angiotensin II receptor antagonist.
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
Development asset linked to Viatris Pharmaceuticals Co in public FDA and regional records.
-
fenofibrate
Cardiovascular system (C10)US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor alpha.
- Target
- Peroxisome proliferator-activated receptor alpha
- Mechanism
- Peroxisome proliferator-activated receptor alpha agonist
-
US regulatory status: approved. Molecular target: Voltage-gated calcium channel.
- Target
- Voltage-gated calcium channel
- Mechanism
- Voltage-gated calcium channel modulator
-
Development asset linked to Viatris Pharmaceuticals Co in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
Development asset linked to Viatris Pharmaceuticals Co in public FDA and regional records.
-
Development asset linked to Viatris Pharmaceuticals Co in public FDA and regional records.
-
Development asset linked to Viatris Pharmaceuticals Co in public FDA and regional records. Molecular target: Nischarin.
- Target
- Nischarin
- Mechanism
- Nischarin agonist
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
Development asset linked to Viatris Pharmaceuticals Co in public FDA and regional records.
-
pregabalin
Nervous system (N02)US regulatory status: approved. Molecular target: Voltage-gated calcium channel.
- Target
- Voltage-gated calcium channel
- Mechanism
- Voltage-gated calcium channel modulator
-
Development asset linked to Viatris Pharmaceuticals Co in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
Development asset linked to Viatris Pharmaceuticals Co in public FDA and regional records.
-
Development asset linked to Viatris Pharmaceuticals Co in public FDA and regional records.
-
Development asset linked to Viatris Pharmaceuticals Co in public FDA and regional records. Mechanism: Norepinephrine transporter inhibitor.
- Mechanism
- Norepinephrine transporter inhibitor
-
Development asset linked to Viatris Pharmaceuticals Co in public FDA and regional records. Mechanism: Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor.
- Mechanism
- Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor